The post Arthur Hayes Calls Fed RMP “QE in Disguise” for Bitcoin appeared on BitcoinEthereumNews.com. BitMEX co-founder Arthur Hayes called the Federal Reserve’The post Arthur Hayes Calls Fed RMP “QE in Disguise” for Bitcoin appeared on BitcoinEthereumNews.com. BitMEX co-founder Arthur Hayes called the Federal Reserve’

Arthur Hayes Calls Fed RMP “QE in Disguise” for Bitcoin

For feedback or concerns regarding this content, please contact us at crypto.news@mexc.com

BitMEX co-founder Arthur Hayes called the Federal Reserve’s Reserve Management Purchases (RMP) program “QE in disguise,” predicting renewed liquidity will drive Bitcoin higher.

Summary

  • Arthur Hayes says the Fed’s RMP program functions like quantitative easing.
  • He expects Bitcoin to trade between $80K–$100K before breaking above $124K.
  • Hayes predicts renewed liquidity could push Bitcoin toward $200K in 2026.

The Maelstrom Fund CIO expects Bitcoin (BTC) to trade between $80,000 and $100,000 near-term before reclaiming $124,000 and potentially targeting $200,000.

Hayes published his analysis in a December 19 essay titled “Love Language,” arguing that RMP functions identically to quantitative easing through indirect mechanisms.

He announced a portfolio shift from Ethereum into high-quality DeFi assets that he believes can outperform as fiat liquidity improves.

RMP operates through money market fund channel

The Fed introduced RMP at the December 10 FOMC meeting. Hayes’ accounting analysis shows the program purchases short-term Treasury bills from money market funds, which then redeploy proceeds into longer-dated Treasuries or repo markets.

This structure indirectly finances government spending without the political costs of formally announcing quantitative easing.

“While RMP purchases are technically smaller in absolute magnitude than past QE programs ($40 billion monthly), the structural mechanism creates equivalent monetary expansion,” Hayes wrote.

The program becomes more powerful through government reliance on T-bill financing to fund deficits exceeding $2 trillion annually.

Hayes emphasized that New York Fed President John Williams has discretionary control over RMP expansion through vague “ample reserves” guidance.

This structure enables unlimited balance sheet expansion with minimal oversight, which Hayes colorfully termed “Money Printer Go F***** Brrrrr.”

Multi-phase Bitcoin price trajectory through 2026

Hayes forecasts choppy trading between $80,000 and $100,000 from December 2025 through January 2026.

Two factors drive this range: persistent belief that RMP differs from quantitative easing and uncertainty about whether the program continues beyond its April 2026 scheduled end.

Once markets recognize RMP’s true quantitative easing nature, Hayes expects quick acceleration.

Bitcoin would quickly retake $124,000 and move toward $200,000 in early-to-mid 2026. This leg would be driven by institutional FOMO, ETF inflows, and recognition that the Fed is underwriting government spending.

March 2026 represents “peak expectations” for RMP’s asset price inflation capability. Hayes anticipates Bitcoin will decline and form a local bottom “well above $124,000.”

The pullback would be temporary and strategic rather than a cycle top. Hayes expanded his long-term forecast to $500,000 by year-end 2026 in late November comments.

Source: https://crypto.news/arthur-hayes-sees-bitcoin-reclaiming-124k/

Market Opportunity
Wink Logo
Wink Price(LIKE)
$0.001698
$0.001698$0.001698
-0.87%
USD
Wink (LIKE) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact crypto.news@mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Key Takeaways Vitalik Buterin wants Ethereum apps built to survive without developers, corporate servers, or trusted third parties Two major […] The post Vitalik
Share
Coindoo2026/03/07 15:49
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26
Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

The post Short-term profit-taking pushes Bitcoin back below key $70K level – What next? appeared on BitcoinEthereumNews.com. Bitcoin [BTC] rallied as high as $74
Share
BitcoinEthereumNews2026/03/07 16:09